LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 40.02% | 45.35% | 40.72% | 20.93% | -31.23% |
| Total Depreciation and Amortization | -23.69% | -68.84% | -54.25% | -41.04% | -21.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.16% | -47.85% | -74.64% | 25.40% | 359.47% |
| Change in Net Operating Assets | 213.08% | -113.23% | -118.32% | -120.98% | -111.36% |
| Cash from Operations | 51.48% | -513.88% | -315,366.67% | -1,091.40% | -1,096.36% |
| Capital Expenditure | 96.85% | 97.59% | 99.27% | 69.76% | -24.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 173.41% | 40.01% | -317.22% | -269.62% | -270.19% |
| Cash from Investing | 170.74% | 45.11% | -336.64% | -280.16% | -288.70% |
| Total Debt Issued | -- | -100.00% | -94.50% | -96.92% | -100.00% |
| Total Debt Repaid | -- | 140.52% | 129.45% | 114.59% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -46.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 149.60% | 193.50% | 215.48% | -100.00% |
| Foreign Exchange rate Adjustments | -186.85% | -79.24% | -94.53% | 107.61% | 143.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.57% | -2,039.01% | -547.37% | -485.84% | -692.79% |